Teva Pharmaceutical's stock rises for seventh straight day

Teva Pharmaceutical Industries (NYSE:TEVA) shares continued their seven-session winning streak, closing 1% higher at $16.59 on Tuesday. The Israeli drugmaker gained 5% in the previous six sessions, but has still lost over 25% this year. The stock's recent performance suggests a potential turnaround, but investors should remain cautious due to its overall decline in 2022.

Teva Pharmaceutical Industries (NYSE:TEVA) shares continued their seven-session winning streak, closing 1% higher at $16.59 on Tuesday. The Israeli drugmaker gained 5% in the previous six sessions, but has still lost over 25% this year. The stock's recent performance suggests a potential turnaround, but investors should remain cautious due to its overall decline in 2022.

Teva Pharmaceutical Industries has been experiencing mixed results. While the company's innovative product portfolio, including its movement disorder therapy Austedo and migraine therapy Ajovy, has shown resilience, the broader healthcare sector's challenges have impacted the company's overall performance. Teva's branded medications failed to offset headwinds in its generics business, leading to missed revenue expectations in Q2 2025 [1].

Despite these challenges, the company has been implementing the "Pivot to Growth" strategy, which has been noted for its resilience in a difficult time for the healthcare sector. Analysts from Seeking Alpha are bullish on the stock, with a Hold rating and a score of 3.12 out of 5. The company received an A- in the prospect of profitability, but an F for growth factor [1].

Teva Pharmaceutical Industries' recent earnings report showed an EPS of $0.66, which exceeded analysts' estimates. However, revenue fell short at $4.18 billion. The stock's performance has been closely followed by institutional investors, with several hedge funds and other institutional investors increasing their holdings in the company. FMR LLC, for instance, lifted its position by 30.7% during the 4th quarter, while Ion Asset Management Ltd. increased its holdings by 6.5% during the 1st quarter [2].

Analysts have also been positive about the stock. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating, while Truist Financial set a "buy" rating and a $25.00 target price. JPMorgan Chase & Co. raised its rating from "neutral" to "overweight" and boosted its target price from $21.00 to $23.00. The consensus rating is "Buy" with an average target price of $24.71 [2].

Investors should continue to monitor Teva Pharmaceutical Industries' performance closely. While the recent gains suggest a potential turnaround, the company's overall decline in 2022 and the challenges faced by the broader healthcare sector warrant caution. The company's ability to execute its "Pivot to Growth" strategy and its innovative product portfolio will be key factors in determining its future success.

References:
[1] https://seekingalpha.com/news/4484082-teva-pharmaceutical-continues-gains-for-seven-straight-sessions
[2] https://www.marketbeat.com/instant-alerts/teva-pharmaceutical-industries-ltd-nyseteva-insider-sells-9176348-in-stock-2025-08-05/